Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of hyperbaric oxygen therapy on cognitive impairment after aneurysm subarachnoid hemorrhage

Junwei Li^1,2, Shaohua Ren², Jinrui Ren², Zigang Zhen², Lirong Li², Xudong Hao², Hongming Ji², Yuanli Zhao¹

¹Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; ²Department of Neurosurgery, The People’s Hospital of Shanxi Province, Taiyuan, China.

For correspondence:- Yuanli Zhao Email: zhaoyuanli@126.com Tel:+861059976611

Accepted: 31 August 2022 Published: 30 September 2022

Citation: Li J, Ren S, Ren J, Zhen Z, Li L, Hao X, et al. Effect of hyperbaric oxygen therapy on cognitive impairment after aneurysm subarachnoid hemorrhage. Trop J Pharm Res 2022; 21(9):1967-1972 doi: 10.4314/tjpr.v21i9.21

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the effect of hyperbaric oxygen therapy (HBOT) on cognitive impairment after aneurysm subarachnoid hemorrhage (aSAH).

Methods: The current study was carried out in a regional neurosurgical center in Taiyuan, Shanxi Province of China from January 2019 to September 2020. A total of 150 patients with persistent cognitive dysfunction at 3 months after aSAH onset were enrolled, which were randomly classified into group A (HBOT) and group B (control) via the random number table method. The outcome was evaluated by Montreal cognitive assessment (MoCA).

Results: There were no significant differences between group A and group B with regard to MoCA score and proportions of normal MoCA patients at 3 months after HBOT (p > 0.05). Both groups showed no significant differences in proportions of normal MoCA patients at 6 months after HBOT (p > 0.05). However, there were significant differences between group A and group B with MoCA score of patients at 6 months after HBOT (p < 0.05). There were also significant differences in MoCA score and proportions of normal MoCA patients at 9 months after HBOT.

Conclusion: HBOT alleviates cognitive impairment after aSAH, and thus may be used to manage cognitive impairment in patients after aSAH. However, further clinical trials are required prior to application in clinical practice.

Keywords: Aneurysm subarachnoid hemorrhage (aSAH), Hyperbaric oxygen therapy (HBOT), Cognitive impairment